Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/20630
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShergis, Johannah Linda-
dc.contributor.authorThien, Francis-
dc.contributor.authorWorsnop, Christopher J-
dc.contributor.authorLin, Lin-
dc.contributor.authorZhang, Anthony L-
dc.contributor.authorWu, Lei-
dc.contributor.authorChen, Yuanbin-
dc.contributor.authorXu, Yinji-
dc.contributor.authorLangton, David-
dc.contributor.authorDa Costa, Cliff-
dc.contributor.authorFong, Harry-
dc.contributor.authorWu, Darong-
dc.contributor.authorStory, David-
dc.contributor.authorXue, Charlie C-
dc.date2019-04-02-
dc.date.accessioned2019-04-15T05:39:50Z-
dc.date.available2019-04-15T05:39:50Z-
dc.date.issued2019-04-02-
dc.identifier.citationThorax 2019; onine first: 2 April-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/20630-
dc.description.abstractPanax ginseng (ginseng) is a therapeutic herb which might be beneficial in COPD. The study investigated if ginseng, compared with placebo, is effective and safe for people with moderate COPD. This multicentre, randomised, double-blind, placebo-controlled trial compared 24 weeks of ginseng capsules (100 mg twice daily) with placebo. Participants were followed up for a further 24 weeks. Participants were aged 40 years and over and had airflow limitation in the moderate (Global Initiative for Chronic Obstructive Lung Disease 2) COPD range. The coprimary endpoints were the St George's Respiratory Questionnaire, the COPD Assessment Test and the Short Form Health Survey. Secondary outcomes included lung function, exacerbation rate and use of relief medication. 168 participants were randomised 1:1 from five centres in Australia and China. Baseline characteristics were balanced between groups. There were no significant differences between ginseng and placebo, with overall results improving in both groups. Ginseng seemed safe for, and well tolerated by, people with COPD. There was no significant difference in improvement in health-related quality of life (primary outcome) between the ginseng and placebo groups. ACTRN12610000768099.-
dc.language.isoeng-
dc.subjectchronic obstructive pulmonary disease-
dc.subjectginseng-
dc.subjectquality of life-
dc.subjectrandomised controlled trial-
dc.title12-month randomised controlled trial of ginseng extract for moderate COPD.-
dc.typeJournal Article-
dc.identifier.journaltitleThorax-
dc.identifier.affiliationDepartment of Respiratory Medicine, Eastern Health, Box Hill, Victoria, Australiaen
dc.identifier.affiliationDepartment of Respiratory Medicine, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationSchool of Science, RMIT University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationFaculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australiaen
dc.identifier.affiliationDepartment of Thoracic Medicine, Frankston Hospital, Frankston, Victoria, Australiaen
dc.identifier.affiliationThe Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China-
dc.identifier.affiliationGuangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China-
dc.identifier.affiliationDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA-
dc.identifier.affiliationSchool of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia-
dc.identifier.doi10.1136/thoraxjnl-2018-212665-
dc.identifier.pubmedid30940771-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.